home / stock / adilw / adilw news

ADILW News and Press, Adial Pharmaceuticals Inc Warrant From 07/22/20

Stock Information
Company Name: Adial Pharmaceuticals Inc Warrant
Stock Symbol: ADILW
Market: NASDAQ
Website: adialpharma.com
Menu
ADILW ADILW Quote ADILW Short ADILW News ADILW Articles ADILW Message Board
Get ADILW Alerts

News, Short Squeeze, Breakout and More Instantly...
ADILW - Adial Pharmaceuticals Receives European Medicines Agency (EMA) Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder

EMA Agreement paves the way for a marketing authorization in Europe after Phase 3 CHARLOTTESVILLE, VA / ACCESSWIRE / July 22, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addict...
ADILW - Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia

CHARLOTTESVILLE, VA / ACCESSWIRE / July 6, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL:ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received approvals in Sweden and Estonia to commence the...

ADILW - Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland

Polish clinical sites initiated less than two weeks after regulatory approval CHARLOTTESVILLE, VA / ACCESSWIRE / June 25, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction,...

ADILW - Adial Pharmaceuticals Announces Commencement of the Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial in Latvia

ONWARD™ trial progresses with the opening of sites in Latvia CHARLOTTESVILLE, VA / ACCESSWIRE / June 17, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today ann...
ADILW - Adial Pharmaceuticals Closes Previously Announced $5.2 Million Registered Direct Offering

CHARLOTTESVILLE, VA / ACCESSWIRE / June 15, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a biopharmaceutical company focused on the development of treatments for addiction and currently conducting the ONWARD™ pivotal Phase 3 clinical trial of its...

ADILW - Adial Pharmaceuticals Receives Order for 1,000 COVID-19 Antibody Test Kits

Initial Customer Order Scheduled for Immediate Delivery Test Kits to Support Efforts in City of Phoenix, Arizona and Surrounding Communities CHARLOTTESVILLE, VA / ACCESSWIRE / June 10, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceu...

ADILW - Adial Pharmaceuticals Announces Pricing of $5.2 Million Registered Direct Offering Priced At-The-Market

CHARLOTTESVILLE, VA / ACCESSWIRE / June 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a biopharmaceutical company focused on the development of treatments for addiction and currently conducting the ONWARD™ pivotal Phase 3 clinical trial of its ...
ADILW - Adial Pharmaceuticals and BioLab Sciences Enter into Distribution Agreement for COVID-19 Antibody Tests

Antibody Testing Available for Landmark ONWARD (TM) Pivotal Phase 3 Trial Participants BioLab Sciences Grants Adial Exclusive Rights to Sell and Distribute Rapid Result COVID-19 Antibody Tests to Designated Channel Partners CHARLOTTESVILLE, VA / ACCESSWIRE / June 8, 2020 / Ad...

ADILW - Adial Pharmaceuticals Appoints Dr. Jack Reich to Board of Directors

CHARLOTTESVILLE, VA / ACCESSWIRE / May 28, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced the appointment of Dr. Jack Reich to the Board of Directors. The appoin...

ADILW - Op-Ed by Adial Pharmaceuticals CEO Published in the Daily Progress

CHARLOTTESVILLE, VA / ACCESSWIRE / May 4, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, announced today that an op-ed written by William Stilley , CEO of Adial Pharmaceuticals...
Previous 10 Next 10